PROSTATE CANCER RESEARCH

The Division of Experimental Pathology has a strong track record of basic and translational research in prostate cancer. Stephen N. Thibodeau, Ph.D. and Daniel Schaid, Ph.D. (Biostatistics) are investigating the genetic basis of familial prostate cancer and how genetic variation contributes to cancer risk in both familial and sporadic prostate cancer cases. Robert B. Jenkins, M.D., Ph.D. uses molecular genetic, cytogenetic and molecular cytogenetics to elucidate the genetic events important for prostate and brain cancer initiation, progression and metastasis. George G. Klee M.D. Ph.D. and George Vazmastis Ph.D. are involved in prostate cancer biomarker discovery. David I. Smith Ph.D. focuses on genomic instability in cancer, and uses molecular and cytogenetic tolls to analyse genes whose expression is altered in prostate cancer. Wanguo Liu Ph.D. studies genes involved DNA damage signaling pathways in prostate cancer. These studies are aimed at understanding the molecular basis of prostate cancer development and progression and aim to identify targets that may be used for risk assessment, diagnosis, monitoring and development of novel therapeutic therapies.